| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2009.25.4706 |
| P698 | PubMed publication ID | 20159816 |
| P50 | author | Jaffer Ajani | Q64913003 |
| P2093 | author name string | Istvan Lang | |
| Gyorgy Bodoky | |||
| Vera Gorbunova | |||
| August Garin | |||
| Ihor Vynnychenko | |||
| Mikhail Lichinitser | |||
| Silvia Falcon | |||
| Vladimir Moiseyenko | |||
| Wuilbert Rodriguez | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| fluorouracil | Q238512 | ||
| adenocarcinoma | Q356033 | ||
| phase III clinical trial | Q42824827 | ||
| gastroesophageal adenocarcinoma | Q61913383 | ||
| cisplatin | Q412415 | ||
| P304 | page(s) | 1547-1553 | |
| P577 | publication date | 2010-02-16 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial | |
| P478 | volume | 28 |
| Q35069199 | 5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells |
| Q37889959 | A Comprehensive Review of S-1 in the Treatment of Advanced Gastric Adenocarcinoma |
| Q35612770 | A Meta-analysis Reveals S-1-based Chemotherapy Improves the Survival of Patients With Advanced Gastric Cancer |
| Q49194716 | A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine |
| Q46396714 | A Phase I Study of Triplet Combination Chemotherapy of Paclitaxel, Cisplatin and S-1 in Patients with Advanced Gastric Cancer |
| Q33395721 | A Phase II Multi-Center Study of Triple Therapy with Paclitaxel, S-1 and Cisplatin in Patients with Advanced Gastric Cancer |
| Q37205013 | A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial. |
| Q43713510 | A feasibility study of outpatient chemotherapy with S-1 + cisplatin in patients with advanced gastric cancer |
| Q84606457 | A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601) |
| Q42370438 | A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma |
| Q33393268 | A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients |
| Q86494622 | A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer |
| Q40839618 | A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer. |
| Q33391384 | A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer |
| Q53492933 | A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer |
| Q64967841 | A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China. |
| Q33409979 | A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site |
| Q50513946 | A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer |
| Q53839706 | A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma |
| Q87904060 | A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial |
| Q40085069 | A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma |
| Q84794314 | A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer |
| Q57805411 | A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study |
| Q58795774 | A prospective phase I study of hypo-fractionated neoadjuvant radiotherapy for locally advanced gastric cancer |
| Q87092998 | A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer |
| Q34348206 | A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II) |
| Q57902299 | A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer |
| Q46388862 | A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer |
| Q38217046 | A systematic review and meta-analysis of gastric cancer treatment in patients with positive peritoneal cytology |
| Q37491365 | Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). |
| Q37191333 | Adjuvant Treatment for Gastric Cancer: Chemotherapy Versus Radiation |
| Q28088619 | Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review |
| Q38047493 | Advanced HER2-positive gastric cancer: Current and future targeted therapies |
| Q39091817 | Advanced gastric adenocarcinoma: optimizing therapy options. |
| Q26764934 | Advanced gastric cancer: Current treatment landscape and future perspectives |
| Q38584644 | Advancing pharmacological treatment options for advanced gastric cancer |
| Q36962398 | An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups |
| Q35208277 | Antitumor effects of a sirtuin inhibitor, tenovin-6, against gastric cancer cells via death receptor 5 up-regulation |
| Q53080933 | Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer |
| Q41823021 | Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens |
| Q38997536 | Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo |
| Q37641014 | Bevacizumab combined with low-dose S-1 as maintenance therapy with a long progression-free survival in an elderly patient with heavily pre-treated advanced gastric cancer: A case report |
| Q38844897 | CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers |
| Q34745772 | CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients |
| Q33433129 | Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis |
| Q34236005 | Capecitabine in gastric cancer |
| Q38645852 | Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis |
| Q41959108 | Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer |
| Q38222270 | Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer |
| Q37059484 | Characteristics and prognosis of gastric cancer in young patients |
| Q38604012 | Chemotherapy for advanced gastric cancer. |
| Q26771424 | Chemotherapy in Elderly Patients with Gastric Cancer |
| Q37832986 | Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard? |
| Q38067752 | Chinese Patients with Gastric Cancer Need Targeted Adjuvant Chemotherapy Schemes |
| Q64273134 | Cisplatin, Fluorouracil in Bolus Injection, and Leucovorin in First-Line Therapy for Advanced Gastric Cancer as an Alternative to Protocols With Infusional Fluorouracil |
| Q48048391 | Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). |
| Q38969972 | Clinical benefits of combined chemotherapy with S-1, oxaliplatin, and docetaxel in advanced gastric cancer patients with palliative surgery |
| Q33609291 | Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer |
| Q53577839 | Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience |
| Q99580477 | Clinical outcomes of capecitabine-based versus S-1-based regimens as first-line chemotherapy in patients with unresectable or metastatic gastric cancer: a propensity score matched single-center comparison |
| Q57453268 | Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer |
| Q38003583 | Clinical trials in gastric cancer and the future |
| Q26785665 | Clinical utility of ramucirumab in advanced gastric cancer |
| Q46721236 | Clinical validation of the EORTC QLQ‐OG25 questionnaire for the evaluation of health‐related quality of life in Mexican patients with esophagogastric cancers |
| Q36078958 | Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis |
| Q34654832 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study |
| Q92511820 | Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance) |
| Q33399154 | Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer |
| Q39462555 | Comparison of advanced adenocarcinomas of esophagogastric junction and distal stomach in Japanese patients |
| Q92201063 | Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: A systematic review and meta-analysis |
| Q52562515 | Comparison of efficacy and tolerance between combination therapy and monotherapy as first-line chemotherapy in elderly patients with advanced gastric cancer: Study protocol for a randomized controlled trial |
| Q50700149 | Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer |
| Q35083334 | Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis |
| Q41542192 | Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). |
| Q35753663 | Complications in advanced or recurrent gastric cancer patients with peritoneal metastasis during and after palliative systemic chemotherapy |
| Q43518078 | Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer |
| Q35002445 | Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1. |
| Q26745453 | Current and emerging therapies in unresectable and recurrent gastric cancer |
| Q38985204 | Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. |
| Q38055905 | Current questions for the treatment of advanced gastric cancer |
| Q37995872 | Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year’s literature |
| Q55033047 | Customization of therapy for gastroesophageal adenocarcinoma patients. |
| Q44664567 | Cytoreductive surgery and Hyperthermic intra-operative peritoneal chemotherapy with Cisplatin for gastric peritoneal Carcinomatosis Monocentric phase-2 nonrandomized prospective clinical trial |
| Q38254307 | DNA synthesis inhibitors for the treatment of gastrointestinal cancer |
| Q64108800 | Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial |
| Q48052472 | Dose-dense biweekly docetaxel combined with 5-fluorouracil as first-line treatment in advanced gastric cancer: a phase II trial |
| Q55155589 | Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer. |
| Q37724518 | Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis |
| Q36224976 | Downregulation of microRNA‑33a promotes cyclin‑dependent kinase 6, cyclin D1 and PIM1 expression and gastric cancer cell proliferation |
| Q47237727 | Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients. |
| Q51366470 | Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors |
| Q33415971 | Effectiveness and safety profile of S-1-based chemotherapy compared with capecitabine-based chemotherapy for advanced gastric and colorectal cancer: A meta-analysis |
| Q92559688 | Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis |
| Q33889328 | Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis |
| Q26865057 | Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis |
| Q43968364 | Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy |
| Q26774720 | Emerging role of S-1 in gastric cancer |
| Q28075698 | Epstein-Barr virus-positive gastric cancer: a distinct molecular subtype of the disease? |
| Q36230473 | Establishment of a triple-negative type human breast cancer cell line that selectively metastasizes to the lung after orthotropic implantation |
| Q86519880 | Evolving Panorama of Treatment for Metastatic Pancreas Adenocarcinoma |
| Q37960206 | Evolving Standards of Care in Advanced Gastric Cancer |
| Q38823374 | Evolving treatments for advanced gastric cancer: appraisal of the survival trend |
| Q37362737 | FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. |
| Q39879882 | Feasibility of an interactive electronic self-report tool for oral cancer therapy in an outpatient setting |
| Q84972214 | Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer |
| Q57918124 | Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis |
| Q39728271 | Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis. |
| Q37959111 | Future Perspectives for the Development of Chemotherapy for Advanced Gastric Cancer: Japanese and Global Status |
| Q89391950 | Gastric cancer |
| Q37591176 | Gastric cancer-molecular and clinical dimensions |
| Q26776195 | Gastric cancer: The times they are a-changin' |
| Q34657361 | Gastric cancer: current status of diagnosis and treatment |
| Q61963099 | Gastric cancer: past progress and present challenges |
| Q37828465 | Gastric cancer: surgery in 2011 |
| Q44734913 | Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression |
| Q38114265 | Geographic differences in approach to advanced gastric cancer: Is there a standard approach? |
| Q38813532 | Global chemotherapy development for gastric cancer |
| Q38314355 | HER2 assessment by silver in situ hybridization: where are we now? |
| Q38210387 | HER2 directed therapy for gastric/esophageal cancers |
| Q89908197 | Hepatic Arterial Infusion Oxaliplatin Plus Oral S-1 Chemotherapy in Gastric Cancer with Unresectable Liver Metastases: A Case Series and Literature Review |
| Q51783859 | Hepatic arterial infusion chemotherapy using fluorouracil, epirubicin, and mitomycin C for patients with liver metastases from gastric cancer after treatment failure of systemic S-1 plus cisplatin |
| Q85609131 | Hepatic sinusoidal obstruction associated with S-1 plus cisplatin chemotherapy for highly advanced gastric cancer with paraaortic lymph node metastases: report of a case |
| Q35940367 | Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study. |
| Q54703477 | Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial. |
| Q92841176 | Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines |
| Q44125251 | Intraoperatively assessed macroscopic serosal changes in patients with curatively resected advanced gastric cancer: clinical implications for prognosis and peritoneal recurrence |
| Q85785131 | Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival |
| Q53676322 | Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes |
| Q42173252 | Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens |
| Q33400558 | Irinotecan plus mitomycin C as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and Cisplatin: a retrospective study |
| Q53379444 | Is chemotherapy in elderly patients with metastatic or recurrent gastric cancer as tolerable and effective as in younger patients? |
| Q64076485 | Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach |
| Q53376236 | Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy |
| Q98612912 | Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China |
| Q41898734 | Latest developments and emerging treatment options in the management of stomach cancer |
| Q36824887 | Lauren classification and individualized chemotherapy in gastric cancer |
| Q43485654 | Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment |
| Q36984821 | MET amplification as a potential therapeutic target in gastric cancer. |
| Q38675350 | MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. |
| Q38157342 | Management of gastric cancer in Asia: resource-stratified guidelines |
| Q34326546 | Medical management of gastric cancer: a 2014 update |
| Q92990086 | Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin |
| Q47830184 | Meta-analysis for the efficacy of S-1-based regimens as the first-line treatment in Asian chemotherapy-naive patients with advanced non-small-cell lung cancer. |
| Q38075499 | Metastatic gastric cancer treatment: a little slow but worthy progress |
| Q41612682 | MicroRNA-200c as a prognostic and sensitivity marker for platinum chemotherapy in advanced gastric cancer |
| Q33413448 | Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study |
| Q55025461 | Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets. |
| Q30500375 | Molecular Classification of Gastric Cancer: A New Paradigm |
| Q50076031 | Multicenter phase II study of capecitabine plus cisplatin as first-line therapy for human epidermal growth factor receptor 2-negative advanced gastric cancer: Yokohama Clinical Oncology Group Study YCOG1107. |
| Q86246485 | Multidisciplinary Management of Gastric Cancer |
| Q26799748 | Multimodal treatment of gastric cancer in the west: Where are we going? |
| Q34340956 | Multimodality management of resectable gastric cancer: A review |
| Q47146995 | Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature |
| Q84107296 | New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points |
| Q36996728 | New and emerging combination therapies for esophageal cancer |
| Q59136693 | New drug developments in metastatic gastric cancer |
| Q39195889 | OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells |
| Q38139297 | Optimal chemotherapy for advanced gastric cancer: is there a global consensus? |
| Q33442681 | Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: meta-analysis |
| Q50647977 | Outcomes in elderly patients treated with a single-agent or combination regimen as first-line chemotherapy for recurrent or metastatic gastric cancer |
| Q47402625 | Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. |
| Q53094324 | Patient heterogeneity and allocation bias: how should they be reported in clinical trials of chemotherapy for advanced gastric cancer? |
| Q92619104 | Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study |
| Q26753865 | Perioperative and Palliative Chemotherapy for Esophageal Cancer |
| Q38169894 | Perioperative chemotherapy in locally advanced gastric cancer. |
| Q26774521 | Personalized medicine in gastric cancer: Where are we and where are we going? |
| Q44150769 | Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer. |
| Q84523134 | Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas |
| Q52851564 | Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer |
| Q33403640 | Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG-0601) |
| Q36822182 | Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma |
| Q57035043 | Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer |
| Q36075265 | Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer |
| Q40914919 | Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer |
| Q33402271 | Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients. |
| Q86096582 | Phase II study of preoperative chemotherapy with S‐1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210) |
| Q56776529 | Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer |
| Q53458025 | Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. |
| Q37560852 | Phase II study on the combination of irinotecan plus cisplatin as a second-line therapy in patients with advanced or recurrent gastric cancer |
| Q30834530 | Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway |
| Q35754239 | Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706). |
| Q28079750 | Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma |
| Q90064455 | Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study |
| Q53227676 | Postgastrectomy pharmacokinetic changes of S-1 in patients with localized advanced gastric cancer |
| Q45722661 | Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer |
| Q39612489 | Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells |
| Q57126061 | Preoperative Nodal F-FDG Avidity Rather than Primary Tumor Avidity Determines the Prognosis of Patients with Advanced Gastric Cancer |
| Q53128686 | Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis |
| Q54497269 | Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. |
| Q33779701 | Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers |
| Q35632548 | Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials |
| Q43870660 | Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy |
| Q39778923 | Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials |
| Q37197679 | Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis |
| Q46350650 | Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). |
| Q64109947 | Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing r |
| Q34669648 | Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002) |
| Q64114506 | Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501) |
| Q38001383 | Randomized trials and quality assurance in gastric cancer surgery |
| Q93041688 | Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines |
| Q34967104 | Recent advances in the HER2 targeted therapy of gastric cancer |
| Q48569564 | Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. |
| Q48145007 | Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review. |
| Q37917630 | Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer |
| Q36611286 | Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia. |
| Q47312073 | Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis |
| Q91688483 | Role of Cancer-Associated Fibroblast in Gastric Cancer Progression and Resistance to Treatments |
| Q38110441 | S-1 (Teysuno®): A Review of Its Use in Advanced Gastric Cancer in Non-Asian Populations |
| Q37974935 | S-1 as a core anticancer fluoropyrimidine agent |
| Q49860695 | S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study |
| Q38031889 | S-1 for the treatment of gastrointestinal cancer |
| Q64966949 | S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study. |
| Q87437188 | S-1 in colorectal cancer: a new standard of care? |
| Q33403790 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial |
| Q35948940 | S-1 treatment leading to complete remission of advanced duodenal adenocarcinoma: A case report |
| Q35070531 | S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis. |
| Q38619215 | S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines |
| Q33415440 | S-1-based versus 5-FU-based chemotherapy as first-line treatment in advanced gastric cancer: a meta-analysis of randomized controlled trials |
| Q27002415 | S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysis |
| Q51352197 | SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma |
| Q36206289 | SOX15 governs transcription in human stratified epithelia and a subset of esophageal adenocarcinomas |
| Q37904800 | Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials |
| Q54970742 | Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer? |
| Q36400378 | Seom guidelines for the treatment of gastric cancer 2015. |
| Q50930365 | Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine |
| Q41044387 | Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis |
| Q34216314 | Stratified phase II trial to establish the usefulness of the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) for advanced gastric cancer |
| Q36334419 | Successful multimodal therapy for an α-fetoprotein-producing gastric cancer patient with simultaneous liver metastases |
| Q34847458 | Surgical treatment for patients with Krukenberg tumor of stomach origin: clinical outcome and prognostic factors analysis |
| Q39234296 | Survival after failure of first-line chemotherapy in advanced gastric cancer patients: differences between Japan and the rest of the world |
| Q33416158 | Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: a meta-analysis. |
| Q38059634 | Systemic Treatment of Gastrointestinal Cancer in Elderly Patients |
| Q37923311 | Systemic therapy for advanced gastric cancer: a clinical practice guideline |
| Q34982764 | Systemic therapy for elderly patients with gastrointestinal cancer. |
| Q34205672 | Targeted therapies for gastric cancer: current status |
| Q38633308 | Targeting HER 2 and angiogenesis in gastric cancer |
| Q35599748 | Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies |
| Q64078991 | The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer |
| Q38941416 | The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis |
| Q24633301 | The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products [...] |
| Q39233316 | The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed. |
| Q60961885 | The clinical outcomes of S-1 plus cisplatin for patients with advanced gastric cancer: A meta-analysis and systematic review |
| Q57758139 | The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010 |
| Q38929099 | The downregulation of miR-200c/141 promotes ZEB1/2 expression and gastric cancer progression |
| Q27318805 | The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis |
| Q64095561 | The optimal neoadjuvant treatment of locally advanced esophageal cancer |
| Q53201331 | The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. |
| Q36097240 | The role of taxanes in the management of gastroesphageal cancer |
| Q35627297 | Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma |
| Q38467530 | Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients |
| Q34137285 | Towards personalized perioperative treatment for advanced gastric cancer. |
| Q47784630 | Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends |
| Q24602875 | Treatment of gastric cancer |
| Q45218658 | Treatment of patients with advanced gastric cancer: experience from an Indian tertiary cancer center |
| Q35688584 | Treatment of resectable gastric cancer |
| Q34661367 | Treatment options in patients with metastatic gastric cancer: current status and future perspectives |
| Q55379237 | Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study. |
| Q46049845 | Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A). |
| Q33432199 | Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis |
| Q39682966 | What is the reference cytotoxic regimen for advanced gastric cancer: standard versus optimal therapy? |
| Q86578814 | [Treatment of gastric cancer] |
Search more.